# Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma

> **NCT00861783** · PHASE1 · COMPLETED · sponsor: **Traws Pharma, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Hepatoma
- Advanced Solid Tumor

## Interventions

- **DRUG:** irinotecan and ON 01910.Na
- **DRUG:** oxaliplatin and ON 01910.Na

## Key facts

- **NCT ID:** NCT00861783
- **Lead sponsor:** Traws Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00861783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00861783, "Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT00861783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*